The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Genetic landscape of ALK+ non-small cell lung cancer (NSCLC) patients (pts) and response to ceritinib in ASCEND-1.
 
Daniel Shao-Weng Tan
Honoraria - Novartis; Pfizer
Consulting or Advisory Role - Bayer; Boehringer Ingelheim; Novartis
Research Funding - Bayer; GlaxoSmithKline; Novartis
Travel, Accommodations, Expenses - Merck; Novartis
 
Dong-Wan Kim
No Relationships to Disclose
 
Michael Thomas
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Novartis; Pfizer; Roche
Research Funding - Novartis (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - AstraZeneca (Inst); Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Novartis; Pfizer; Roche
 
Serafino Pantano
Employment - Novartis; Novartis (I)
Stock and Other Ownership Interests - Novartis; Novartis (I)
Patents, Royalties, Other Intellectual Property - Novartis
 
Ying Wang
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Sebastian Lukasz Szpakowski
Employment - Alexion Pharmaceuticals; Novartis; Sarepta Therapeutics
Stock and Other Ownership Interests - Alexion Pharmaceuticals; Novartis; Sarepta Therapeutics
 
Alejandro Javier Yovine
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Ranee Mehra
Employment - GlaxoSmithKline (I)
Stock and Other Ownership Interests - GlaxoSmithKline (I)
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Genentech; Novartis
Research Funding - Genentech
Travel, Accommodations, Expenses - Mirati Therapeutics
 
Laura Q. Chow
Honoraria - Amgen; Astellas Pharma; Emergent BioSolutions; Merck; Novartis
Consulting or Advisory Role - Amgen; Emergent BioSolutions; Merck; Novartis
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); ImClone Systems (Inst); Incyte (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); NCCN (Inst); Novartis (Inst); Pfizer (Inst); VentiRx (Inst)
Travel, Accommodations, Expenses - Merck; Novartis
 
Sunil Sharma
Stock and Other Ownership Interests - Beta Cat Pharmaceuticals; ConverGene; Salarius Pharmaceuticals
Honoraria - Blend Therapeutics; Foundation Medicine; Guardant Health; Novartis; Novartis; Novartis
Research Funding - Amgen (Inst); Bayer (Inst); Blueprint Medicines (Inst); Celgene (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Johnson & Johnson (Inst); Labceutics (Inst); Labceutics (Inst); MedImmune (Inst); Merck (Inst); Merrimack (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Onyx (Inst); Plexxikon (Inst); Sanofi (Inst); Spectrum Pharmaceuticals (Inst); XuanZhu (Inst)
Patents, Royalties, Other Intellectual Property - Patent Pending: “Substituted N-Phenylpyrimidin-2-Amine Analogs as Inhibitors of the AXL Kinase”. U.S. Patent No. WO 2012135800 A1 20121004. Washington, D.C.:U.S. Patent and Trademark Office.; Patent: “Substituted 3-(IH-Benzo[D]Imidazol-2-YL)-IH-Indazole Analogs as Inhibitors of the PDKI Kinase”. U.S. Patent No. WO 2012135799 A1 20121004. Washington, D.C.:U.S. Patent and Trademark Office.; Patent: “Substituted N-(3-(Pyrimidin-4-YL)Phenyl)Acrylamide Analogs as Tyrosine Receptor Kinase BTK Inhibitors”. U.S. Patent No. US 8,703,767 B2. Washington, D.C.:U.S. Patent and Trademark Office.
 
Benjamin J. Solomon
Honoraria - AstraZeneca; Bristol-Myers Squibb
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb (Inst); Eisai; Merck Sharp & Dohme (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Research Funding - Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from Veristrat (Biodesix)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Merck; Roche
 
Enriqueta Felip
Honoraria - Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; MSD; Novartis; Pfizer; Roche
Speakers' Bureau - Bristol-Myers Squibb; Novartis; Roche
 
D. Ross Camidge
Honoraria - Novartis
 
Johan F. Vansteenkiste
Consulting or Advisory Role - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst)
Research Funding - AstraZeneca (Inst)
 
Hans Bitter
Employment - Novartis
 
Lilli M. Petruzzelli
Employment - Novartis
Stock and Other Ownership Interests - Amgen; Amgen (I); Gilead Sciences; Gilead Sciences (I); Johnson & Johnson; Johnson & Johnson (I); Merck; Merck (I); Novartis; Novartis (I); Pfizer; Pfizer (I)
 
Margaret Han Dugan
Employment - Novartis
 
Alice T. Shaw
Honoraria - Novartis; Pfizer; Roche
Consulting or Advisory Role - Ariad; Blueprint Medicines; Daiichi Sankyo; EMD Serono; Genentech; Ignyta; Novartis; Pfizer; Roche; Taiho Pharmaceutical
Research Funding - Novartis; Pfizer; Roche/Genentech